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Background/aim: Preeclampsia is a leading cause of maternal death in the developing world. Our aim was to quantify and compare
messenger (mRNA) expression of nuclear factor-kappa beta (NF-κΒ) and superoxide dismutase (SOD) in control patients with
preeclampsia and without preeclampsia with or without familial hereditary background.
Materials and methods: Four groups of patients were formed depending on the presence or absence of preeclampsia and presence or
absence of familial history for preeclampsia. NF-κΒ and SOD were measured in human placentas by real-time quantitative polymerase
chain reaction. The 2–ΔΔct analysis method was used to measure the difference in the relative expression of the target genes in each
group of patients.
Results: In NF-κΒ expression, there was an increase of 23.35% in the group of women with preeclampsia versus women with preeclampsia
without familial history. Regarding SOD, there was a reduction of about 33.33% in the expression in women with preeclampsia with
familial history versus women with preeclampsia without familial history.
Conclusion: Familial presence of preeclampsia could predispose to altered expression in SOD and NF-κΒ.
Key words: Genetic background, preeclampsia, nuclear factor-kappa beta, superoxide dismutase

1. Introduction
Preeclampsia is a multisystemic and multifactorial
disease and complicates 2%–8% of pregnancies after 20
weeks of gestation, being the leading cause of maternal
death in developing countries and a major contributor to
maternal and perinatal morbidity. Globally, preeclampsia
and eclampsia account for 10%–15% of maternal deaths.
The majority of these deaths in developing countries
result from eclampsia, while in developed countries,
complications of preeclampsia are more often the cause
(1). In Mexico, preeclampsia represents up to 34% of
all maternal deaths, being the leading cause of deathassociated pregnancy complications (2,3). There is a
certain type of complex inheritance in this disease: some
studies postulate that persons with a familial history
of preeclampsia are more susceptible to this disease.
For example, Darcy et al. described that women with
preeclampsia were 2.3 times more likely to have a female
sibling who also had preeclampsia (4). A study carried
out by Esplin et al. also found that both men and women
who were the product of a pregnancy complicated by
preeclampsia were significantly more likely than control
* Correspondence: mezh_74@yahoo.com

men and women to have a child who was the product
of a pregnancy complicated by preeclampsia (5). The
greater likelihood of preeclampsia among relatives with
a previous preeclamptic pregnancy is consistent with the
pathophysiological role for genetics and/or behavioral
factors that cluster in families.
Normal pregnancy exhibits an increase in free radical
(FR) production; in parallel, antioxidant defenses also
increase the maintenance of balance in the redox state (6).
In contrast to normal pregnancy, there is an imbalance
in the redox state in preeclampsia, i.e. women with
preeclampsia exhibit an increased production of FRs
and, at the same time, a decrease in several important
antioxidants, generating oxidative stress (OS) with
consequent damage to the entire class of important
molecules such as DNA, proteins, unsaturated fatty acids,
etc., and overstimulation of lipid peroxidation (7,8).
During a preeclampsia-complicated pregnancy, catalase
activity increases and superoxide dismutase (SOD) and
glutathione reductase (GR) activity decreases compared
with the same parameters during physiological pregnancy
(9).

783

SILVA CARMONA and MENDIETA ZERÓN / Turk J Med Sci
Recently, it is has come to be known that, in addition
to the direct damage that FRs can inflict on the molecules,
imbalance in the redox state can alter the normal
expression of various signaling pathways that comply
with the physiological functions necessary to maintain the
organisms’ homeostasis (10,11). One of these signaling
pathways is the nuclear factor-kappa beta (NF-κΒ)
pathway (12). This transcription factor is critical for a
wide range of physiological processes, such as immunity,
cell development, growth, and survival; however, aberrant
activation of NF-κΒ could lead to morbid states (13). The
aim of this study was to compare NF-κΒ and SOD gene
expression in women who had suffered preeclampsia or
not with or without familial history.
2. Materials and methods
This was a cross-sectional, prospective, nonrandomized,
and descriptive study developed from March 2012 to
February 2013, approved by the Ethics Committees of
the Maternal-Perinatal Hospital “Mónica Pretelini Saénz”
(HMPMPS) (2010-12-156), Health Institute of the State
of Mexico (ISEM), and the Medical Sciences Research
Center (CICMED), Autonomous University of the State of
Mexico (UAEMex) (2010/02), and performed according to
the ethical standards of the Helsinki Declaration of 1964.
Written informed consent was obtained from all patients.
2.1. Patients
Pregnant women were recruited at the HMPMPS,
ISEM, Toluca, Mexico. All subjects with chronic medical
disorders such as diabetes mellitus, cardiovascular disease,
autoimmune disease, chronic renal disease, chronic
hypertension, collagen disorder, and other chronic disease
were excluded.
Four groups were formed as follows: a) normal
pregnancies; b) normal pregnancies with familial history
of preeclampsia; c) women with preeclampsia with familial
history of preeclampsia, and d) women with preeclampsia
without familial history of preeclampsia. The definition
of and the criteria for preeclampsia were based on the
diagnostic criteria outlined by the American College
of Obstetrics and Gynecology (14). The sample was
considered at convenience during the year of follow-up.

2.2. Clinical measurements
Weight (kg), height (m; Seca, GmbH, Germany), and waist
circumference (cm) of all participants were measured in
the morning. Body mass index was calculated as weight
(kg) divided by height (m) squared. Blood pressure
was recorded at each patient visit using a standard
sphygmomanometer (Riester Big Ben® Square, Germany)
with an appropriately sized cuff.
2.3. Laboratory analysis
All patients underwent standard care, including routine
laboratory tests, with an 8-h fasting period: albumin (mg/
dL); cholesterol (mg/dL); creatinine (mg/dL); glucose
(mg/dL); triglycerides (mg/dL); uric acid (mg/dL); liver
profile (Dimension R × L Max; Dade Behring, USA),
and hematological parameters (Advia 120; Bayer Health,
Germany). All these tests were measured at the HMPMPS
according to standardized procedures recommended by
the International Federation of Clinical Chemistry and
Laboratory Medicine.
2.4. Placental samples
Placental tissue samples were isolated a few minutes after
delivery. Tissues were dissected from the maternal side in
areas free of visible infarction, calcification, hematoma, or
tears. The dimensions of each sample were approximately
1‒3 cm3 and 100 mg wet weight. The basal and chorionic
plates were removed, and each sample was washed
three times with ice-cold calcium and magnesiumfree phosphate-buffered saline solution. Immediately
afterward, the tissue was stored at –80 °C until analysis.
2.5. mRNA extraction
The samples were homogenized using a Bullet Blender
Standard BBX24 instrument (Next Advance, Inc., USA).
Messenger RNA (mRNA) was extracted using the Magna
Pure LC RNA isolation kit III (Roche, Germany) in the
Magna Pure LC 2.0 Instrument. The A260/280 nm absorbance
ratio was >1.8 (quality) and total RNA concentration
was calculated by determining absorbance at 260 nm
established with the NanoPhotometer (Implen GmbH,
Germany).
2.6. cDNA synthesis
A total of 200–400 ng of total mRNA was reversetranscribed to complementary DNA (cDNA) using a

Table 1. Primer sequences.
Gene

Forward

Reverse

GAPDH

5’-ctttggtatcgtggaaggactc-3’

5’-gtagaggcagggatgatgttct-3’

NF-κΒ

5’-tgggaatccagtgtgtgaag-3’

5’-cacagcattcaggtcgtagt-3’

SOD2

5’-gcctacgtgaacaacctgaa-3’

5’-gccgtcagcttctccttaaa-3’

GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; NF-κΒ: nuclear factorkappa-beta, SOD2: superoxide dismutase 2.
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Transcriptor High Fidelity cDNA Synthesis Kit (Roche).
The samples were measured with a NanoPhotometer
(Implen GmbH), and the extracts were then adjusted to a
concentration of 20 µg of DNA for the PCR reaction.
The primers used in the experiments were designed
using the Primer Quest web tool (Integrated DNA
Technologies, Inc., USA) and synthesized at the
Synthesis and DNA Sequencing Unit of the National
Autonomous University of Mexico (UNAM) Institute of
Biotechnology (Cuernavaca, Morelos, Mexico). A BLAST
search was performed on primer sequences to ensure
oligohybridization of only specific products. The sequences
of the primers used in the analysis are depicted in Table 2.
Real-time quantitative polymerase chain reaction
(qPCR) was performed with the 7500 Fast Real Time PCR
System (Applied Biosystems, Applera UK, Cheshire, UK).
The final reaction volume (20 µL) contained 10 µL of SYBR
Advantage qPCR premix (2X), 0.4 µL of each forward and
reverse oligonucleotide, 0.4 µL of ROX Reference Dye
LSR or LMP (50X), 2 µL of template, and 6.8 µL of dH2O
(SYBR Advantage q-PCR Premix; Clontech, USA). The
final concentration of each gene was optimized according
to the final results calculated with the Taguchi method.
The thermal cycling conditions were as follows: 10 min at
95 °C followed by 45 cycles of denaturation at 95 °C for 15
s and annealing/extension at 60 °C for 1 min.
The fold change in NF-κΒ and SOD was normalized
against glyceraldehyde 3-phosphate dehydrogenase

(GAPDH) and then compared with the untreated controls
(calibration sample) with the delta-delta-(CT) method
(2–ΔΔCT) as follows: = (CT-target – CT-reference) treatedsample – (CT-target – CT-reference) calibrator-sample,
where CT = threshold cycle. Calibrator-sample refers to
the expression level (1×) of the target gene normalized to
the constitutive gene. The calibrator was chosen from the
group of women with normal pregnancies without familial
history of preeclampsia.
2.7. Statistical analysis
Anthropometric and laboratorial results were presented
as median (range), and those of genetic expression were
presented as mean ± standard error (SE). The Mann–
Whitney U test was used for variables that were not
normally distributed. The normality hypothesis was tested
utilizing the Kolmogorov–Smirnov test. Statistical analysis
was performed using SPSS 20.0. In all cases, P ≤ 0.05 was
considered statistically significant.
3. Results
3.1. General patient characteristics
We studied 31 pregnant women with mean age of 22.3 ± 3.4
years: eight with normal pregnancies, eight with normal
pregnancies but with familial antecedents of preeclampsia,
seven with preeclampsia without familial history, and
seven with preeclampsia with familial history.
Taking into account all women with a previous case
of preeclampsia in their family (N = 15), the mothers

Table 2. Clinical and laboratorial characteristics.1
Group
Variable

Healthy pregnancies

Healthy pregnanciesa

Preeclampsia

Preeclampsiaa

Age (years)**&

20.5 (17–25)

24 (17–25)

25 (22–29)

22 (16–26)

BMI (kg/m2)

26.2 (19.3–40)

26.6 (23.2–33.3)

28.6 (22.5–32.9)

31.2 (22.5–33.1)

Pregnancies

2 (1–4)

2.5 (1–4)

1 (1–2)

1 (1–5)

Prenatal consultations

6.5 (5–9)

6 (5–8)

6 (5–7)

5 (2–7)

Baby weight (kg)

3 (2.9–3.8)

2.8 (2.2–3.7)

3.6 (2–4)

2.9 (2.4–3.8)

SBP (mmHg)**

111.5 (104–125)

121 (88–145)

138 (100–152)

133 (110–150)

DBP (mmHg)*ŧ

68 (59–85)

73 (49–88)

81 (67–106)

80 (70–90)

MBP (mmHg)*

83.3 (74–98.3)

89.8 (69–107)

100 (78.7–121.3)

96 (90–110)

Leukocytes (cells/mm3)

7500 (6000–15,300)

9000 (6100–12,300)

8900 (4500–14,000)

7700 (6300–10,200)

Erythrocytes (cells /mm )

4.5 (3.8–5.3)

4.5 (4.1–4.7)

4.4 (3.7–4.9)

4.2 (4–4.9)

Hb (g/dL)

13.5 (9.7–15.2)

13.3 (12.1–14.3)

13.2 (8.9–14.9)

12.7 (10.9–14.9)

235 (108–269)

216 (165–376)

145 (122–263)

181 (147–313)

ŧ

ŧ

b

3

Platelets (cells /mm )
c

3

1
Median (range); BMI: body mass index, Hb: hemoglobin, SBP: systolic blood pressure, DBP: diastolic blood pressure, MBP: median
blood pressure. a: With family history for preeclampsia, b: millions, c: thousands. &: Difference between healthy women and preeclamptic
women with familial history; ŧ: difference between healthy women and preeclamptic women without familial history.
*: P < 0.05; **: P < 0.01.
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represented 40% (N = 6) and their female siblings 60% of
the affected relatives (N = 9).
Primi- or multiparous women with a new sexual
partner constituted 50% (4 of 8) of the healthy group of
pregnancies without a familial history of preeclampsia,
37.5% (3 of 8) of the healthy group of pregnancies with
familial history, 71.4% (5 of 7) of the group of women with
preeclampsia without familial history, and 85.7% (6 of 7)
of the group of women with preeclampsia with familial
history.
There were statistical differences in systolic (P < 0.01),
diastolic (P < 0.05), and mean blood pressure (P < 0.05)
between healthy women and women with preeclampsia
without familial history. The only difference between
healthy women and pregnant women with preeclampsia
with familial history was in age (P < 0.01). Among
laboratory data, there were no statistical significant
differences in the hematological variables (Table 2).
When comparing the two groups with preeclampsia,
women with affected relatives showed lower levels of
uric acid (P < 0.05). Lactate dehydrogenase exhibited
a tendency to be higher in the group with affected firstdegree relatives (P = 0.053).
3.2. Gene expression
Upon analyzing the normalized CT values with the
Kruskal–Wallis test, there were no statistically significant
differences in either the expression of NF-κΒ or SOD
among the four groups (Table 3) (Figures 1A and 1B).
Notwithstanding the lack of statistical difference, there was
a reduction of about 33.33% in SOD expression in women
with preeclampsia versus women with preeclampsia
without familial history. Regarding NF-κΒ, there was
an increase of 23.35% in the group of women with
preeclampsia versus women with preeclampsia without
familial history. When including all of the patients, only
in two groups, that is, normal pregnancies and those of
women with preeclampsia, was there also no difference in
genetic expression.
4. Discussion
A large amount of investigation has shown a genetic
association between a multifactorial polygenic inheritance

and the development of preeclampsia (15). The risk of
developing preeclampsia is increased five times in women
with first-degree relatives with this disease, while those
with second-degree relatives with the disease have their
risk doubled (16). However, paternal genes may also play
an important role in the development of preeclampsia,
because the risk of this disease is increased in women with
the pregnancies of men who have previously been involved
in pregnancies complicated by preeclampsia (17).
Over 70 biological candidate genes have been
examined, representing pathways involved in various
pathophysiological processes, including vasoactive
proteins, thrombophilia, hypofibrinolysis, OS and lipid
metabolism, endothelial injury, and immunogenetics
(18,19). These findings and others suggest a multifactorial
polygenic inheritance with a genetic component in the
development of this disease (20). In analyzing OS, SOD
probably possesses a tendency to be decreased in women
with a familial history of preeclampsia.
Even more, several microarray studies have analyzed
the transcriptome of preeclamptic placentas for identifying
genes that could be involved in placental dysfunction.
Some of the promoters of upregulated genes are enriched
in putative binding sites for NF-κΒ (21), which determines
an inflammatory response (22). Contrariwise, specific
inhibitors of p38 mitogen-activated protein kinase and
NF-κΒ, but not protein kinase C signaling pathways, can
reduce the stimulatory effect of interleukin-1 beta (23).
It has only been in recent years, as susceptibility genes
for other complex disorders have been reported, that
the effect of the small size of individual genetic variants
have become apparent, the majority increasing the risk
for disease by <50% (24). In this study, we compared
NF-κΒ and SOD expression in pregnant women with or
without preeclampsia and familial history of this disease.
Although there were expected changes in the relative
expression of both genes when there was familial history
for preeclampsia, these modifications were not sufficiently
strong to achieve statistical difference.
A limitation of this study is the small sample size of each
group; however, investigation concerning preeclampsia is
time-consuming and, similar to other studies (25,26), we

Table 3. Relative gene expression.1
Group
Gene

Healthy pregnancies

Healthy pregnanciesa

Preeclampsia

Preeclampsiaa

NF-κΒ

4.84 (2)

3.29 (1.1)

6.55 (3.1)

8.08 (1.7)

SOD

3.17 (2.8)

6.68 (3.3)

2.82 (1.2)

1.88 (0.7)

Median (standard error [SE]). NF-κΒ: Nuclear factor-kappa-B, SOD: superoxide dismutase. a: With family
history for preeclampsia.
1
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A

B
12.0

10.0

mRNA SOD (Relative units)

mRNA NFKB (Relative units)

12.0

8.0
6.0
4.0
2.0
0.0

Healthy

Healthy with
Preeclamptic
familial history
GROUP

10.0
8.0

6.0
4.0
2.0
0.0

Preeclamptic with
familial history

Healthy

Healthy with
Preeclamptic
familial history
GROUP

Preeclamptic with
familial history

Figure 1. A) Messenger RNA (mRNA) expression of NF-κΒ, B) mRNA expression of SOD. NF-κΒ: Nuclear factor kappa-beta; SOD:
superoxide dismutase.

think that analysis of novel molecules is valid in a small
population as an initial approach.
While it is noteworthy that no one gene will be identified
as the sole risk factor for preeclampsia, interactions
among numerous pathways activated by several genes
and/or single nucleotide polymorphisms, in addition to
predisposing environmental factors, are most likely to
underscore the genetic component of this disorder
Our study implies that the familial presence of
preeclampsia could predispose to an altered expression
in SOD and NF-κΒ, partially explaining the genetic
background that predisposes to a higher risk of this disease.
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